X

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Jun 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Edasalonexent (Primary)
Indications Duchenne muscular dystrophy
Focus Registrational; Therapeutic Use
Acronyms POLARIS DMD
Sponsors Astria Therapeutics; Catabasis Pharmaceuticals

Most Recent Events

19 Nov 2020 Status changed from active, no longer recruiting to completed.
10 Nov 2020 This trial has been completed in Sweden (Global End Date: 22 Sep 2020), according to European Clinical Trials Database record.
26 Oct 2020 According to a Catabasis Pharmaceuticals media release, Data from this trial will be further analyzed and are expected to be presented at an upcoming scientific conference and published.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com